Viking Therapeutics

World Rank (Aug-2026)

4274

Market Cap (Aug-2026)

3.872 Billion USD

Market Cap (Mar-08-2026)

3.811 Billion USD

World Rank (Jan-05-2024)

5,954

Market Cap (Jan-05-2024)

1.859 Billion USD

World Rank (Jul-30-2023)

7,050

Market Cap (Jul-30-2023)

1.442 Billion USD

World Rank (Jan-07-2022)

16,059

Market Cap (Jan-07-2022)

0.329 Billion USD

World Rank (Jan-01-2021)

12,134

Market Cap (Jan-01-2021)

0.411 Billion USD

Headquarters Country

USA

Nasdaq / NYSE Code

VKTX

Employee Count

18

Employee Count as of Date

As on 2021

Headquarters City/State

California

World Region

Americas

World Subregion

Northern America

Annual Revenue in USD

0 Million USD

Annual Operating Income in USD

-393 Million USD

Annual Net Income in USD

-360 Million USD

Annual Results for Period Ending

For year ending December-2025

Total Assets in USD

716 Million USD

Total Liabilities in USD

77 Million USD

Total Equity in USD

639 Million USD

Balance Sheet for Period Ending

As of December-2025

Business Sector

Company Website

Yahoo

Company Profile

Viking Therapeutics is a Clinical Stage Biopharmaceutical company. It is focused on the development of novel, orally available, first in class or best in class therapies for the treatment of metabolic and endocrine disorders. The company annual revenue is 7.3 million USD and 15 employees as 2019. The headquarters is in USA.

Founded Year

2012

IPO Year

2015

Stock Exchange

Nasdaq

Nasdaq Sector

Health Care

Nasdaq Industry

Biotechnology: Pharmaceutical Preparations